Literature DB >> 18594948

In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma.

G Di Giacomo1, A Lentini, S Beninati, M Piacentini, C Rodolfo.   

Abstract

One of the most relevant problems in tumour treatment resides on the ability of the tumour to form metastasis and disseminate among the organism. The formation of metastases is a complex process, which requires the action of various effectors, not yet completely identified. The analysis of various types of tumours revealed a complex picture about the relationship between type 2 transglutaminase (TG2) expression and outcome and/or metastatic potential of the tumour itself. In some tumours, the transition to a highly invasive state is paralleled by an up-regulation of TG2 expression and/or activity while in some other a down-regulation has been reported. In addition, host tissues seem to react to tumour invasion by up-regulating TG2 expression. In order to analyse whether TG2 might be involved in the metastatic process in melanoma, we studied the metastases formation and development by means of the B16-F10 murine melanoma cell line and with TG2(-/-) mice as experimental model. Our results indicate that TG2 absence in the host is a favouring condition for the formation and development of the metastasis, while the presence of TG2 in the tumour's cell might be requested for the development of the metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594948     DOI: 10.1007/s00726-008-0119-5

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  9 in total

1.  GPR56 inhibits melanoma growth by internalizing and degrading its ligand TG2.

Authors:  Liquan Yang; Scott Friedland; Nancy Corson; Lei Xu
Journal:  Cancer Res       Date:  2013-12-19       Impact factor: 12.701

Review 2.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

3.  Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations.

Authors:  Junyoung Choi; Shinkyo Yoon; Deokhoon Kim; Yong Wha Moon; Chang Hoon Lee; Seyoung Seo; Jaekyung Cheon; Yong Song Gho; Changhoon Kim; Eung Ryoung Lee; Soo-Youl Kim; Kyoungmin Lee; Joo Young Ha; Sook Ryun Park; Sang-We Kim; Kang-Seo Park; Dae Ho Lee
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

4.  Targeted Quantitative Profiling of GTP-Binding Proteins Associated with Metastasis of Melanoma Cells.

Authors:  Rong Cai; David Bade; Xiaochuan Liu; Ming Huang; Tianyu F Qi; Yinsheng Wang
Journal:  J Proteome Res       Date:  2021-10-25       Impact factor: 4.466

5.  Separation and identification of HSP-associated protein complexes from pancreatic cancer cell lines using 2D CN/SDS-PAGE coupled with mass spectrometry.

Authors:  Zhiyun Zhao; Hui Liu; Xinli Wang; Xiaodong Wang; Zhili Li
Journal:  J Biomed Biotechnol       Date:  2011-10-19

6.  Identifying and targeting determinants of melanoma cellular invasion.

Authors:  Aparna Jayachandran; Prashanth Prithviraj; Pu-Han Lo; Marzena Walkiewicz; Matthew Anaka; Briannyn L Woods; BeeShin Tan; Andreas Behren; Jonathan Cebon; Sonja J McKeown
Journal:  Oncotarget       Date:  2016-07-05

Review 7.  The Role of Tissue Transglutaminase in Cancer Cell Initiation, Survival and Progression.

Authors:  Claudio Tabolacci; Angelo De Martino; Carlo Mischiati; Giordana Feriotto; Simone Beninati
Journal:  Med Sci (Basel)       Date:  2019-01-25

8.  Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells.

Authors:  Aparna Jayachandran; Sonja J McKeown; Briannyn L Woods; Prashanth Prithviraj; Jonathan Cebon
Journal:  Front Oncol       Date:  2015-02-16       Impact factor: 6.244

Review 9.  Role of Transglutaminase 2 in Migration of Tumor Cells and How Mouse Models Fit.

Authors:  Ajna Bihorac
Journal:  Med Sci (Basel)       Date:  2018-08-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.